174 related articles for article (PubMed ID: 27764800)
21. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Chapman JA; Sgroi DC; Goss PE; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Badovinac-Crnjevic T; Shepherd LE; Pollak MN
Breast Cancer Res Treat; 2016 May; 157(1):101-8. PubMed ID: 27116182
[TBL] [Abstract][Full Text] [Related]
22. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
23. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
24. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
Todorovic-Rakovic N; Neskovic-Konstantinovic Z
J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
[TBL] [Abstract][Full Text] [Related]
25. FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors.
Marian C; Ochs-Balcom HM; Nie J; Kallakury BV; Ambrosone CB; Trevisan M; Edge S; Shields PG; Freudenheim JL
Int J Cancer; 2011 Aug; 129(3):702-12. PubMed ID: 20853316
[TBL] [Abstract][Full Text] [Related]
26. Assessing interactions between the associations of fibroblast growth factor receptor 2 common genetic variants and hormone receptor status with breast cancer risk.
Wang H; Yang Z; Zhang H
Breast Cancer Res Treat; 2013 Jan; 137(2):511-22. PubMed ID: 23184080
[TBL] [Abstract][Full Text] [Related]
27. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
29. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.
Akisik E; Dalay N
Exp Mol Pathol; 2004 Jun; 76(3):260-3. PubMed ID: 15126109
[TBL] [Abstract][Full Text] [Related]
30. Genome-Wide Transcriptome Analysis of Estrogen Receptor-Positive and Human Epithelial Growth Factor Receptor 2-Positive Breast Cancers by Ribonucleic Acid Sequencing.
Chen P; Song W; Liu L
Gynecol Obstet Invest; 2018; 83(4):338-348. PubMed ID: 29241203
[TBL] [Abstract][Full Text] [Related]
31. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
32. Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation.
Ghoussaini M; French JD; Michailidou K; Nord S; Beesley J; Canisus S; Hillman KM; Kaufmann S; Sivakumaran H; Moradi Marjaneh M; Lee JS; Dennis J; Bolla MK; Wang Q; Dicks E; Milne RL; Hopper JL; Southey MC; Schmidt MK; Broeks A; Muir K; Lophatananon A; Fasching PA; Beckmann MW; Fletcher O; Johnson N; Sawyer EJ; Tomlinson I; Burwinkel B; Marme F; Guénel P; Truong T; Bojesen SE; Flyger H; Benitez J; González-Neira A; Alonso MR; Pita G; Neuhausen SL; Anton-Culver H; Brenner H; Arndt V; Meindl A; Schmutzler RK; Brauch H; Hamann U; Tessier DC; Vincent D; Nevanlinna H; Khan S; Matsuo K; Ito H; Dörk T; Bogdanova NV; Lindblom A; Margolin S; Mannermaa A; Kosma VM; ; Wu AH; Van Den Berg D; Lambrechts D; Floris G; Chang-Claude J; Rudolph A; Radice P; Barile M; Couch FJ; Hallberg E; Giles GG; Haiman CA; Le Marchand L; Goldberg MS; Teo SH; Yip CH; Borresen-Dale AL; ; Zheng W; Cai Q; Winqvist R; Pylkäs K; Andrulis IL; Devilee P; Tollenaar RA; García-Closas M; Figueroa J; Hall P; Czene K; Brand JS; Darabi H; Eriksson M; Hooning MJ; Koppert LB; Li J; Shu XO; Zheng Y; Cox A; Cross SS; Shah M; Rhenius V; Choi JY; Kang D; Hartman M; Chia KS; Kabisch M; Torres D; Luccarini C; Conroy DM; Jakubowska A; Lubinski J; Sangrajrang S; Brennan P; Olswold C; Slager S; Shen CY; Hou MF; Swerdlow A; Schoemaker MJ; Simard J; Pharoah PD; Kristensen V; Chenevix-Trench G; Easton DF; Dunning AM; Edwards SL
Am J Hum Genet; 2016 Oct; 99(4):903-911. PubMed ID: 27640304
[TBL] [Abstract][Full Text] [Related]
33. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of FGFR2 gene polymorphism in women with breast cancer.
Salehi Z; Afzali S; Shabanipour S; Rahimi A
Cell Mol Biol (Noisy-le-grand); 2015 May; 61(2):94-7. PubMed ID: 26025410
[TBL] [Abstract][Full Text] [Related]
35. FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: results of a case control study in Japan.
Kawase T; Matsuo K; Suzuki T; Hiraki A; Watanabe M; Iwata H; Tanaka H; Tajima K
Int J Cancer; 2009 Oct; 125(8):1946-52. PubMed ID: 19582883
[TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
37. HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.
Watrowski R; Castillo-Tong DC; Wolf A; Schuster E; Fischer MB; Speiser P; Zeillinger R
Anticancer Res; 2015 Nov; 35(11):5901-4. PubMed ID: 26504013
[TBL] [Abstract][Full Text] [Related]
38. Risk of genome-wide association study newly identified genetic variants for breast cancer in Chinese women of Heilongjiang Province.
Jiang Y; Han J; Liu J; Zhang G; Wang L; Liu F; Zhang X; Zhao Y; Pang D
Breast Cancer Res Treat; 2011 Jul; 128(1):251-7. PubMed ID: 21197568
[TBL] [Abstract][Full Text] [Related]
39. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
40. Association of single nucleotide polymorphisms in FGF-RAS/MAP signalling cascade with breast cancer susceptibility.
Dankova Z; Zubor P; Grendar M; Kapinova A; Zelinova K; Jagelkova M; Gondova A; Dokus K; Kalman M; Lasabova Z; Danko J
Gen Physiol Biophys; 2017 Dec; 36(5):565-572. PubMed ID: 29372690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
